Phase II data show durable responses in head and neck cancer
QBiotics has announced positive results from its Phase II QB46C-H08 trial, with tigilanol tiglate achieving a 78% Objective Response Rate (ORR) in patients with head and neck solid malignancies who were refractory to standard of care.
The company says the result, based on 14 responses across 18 injected tumours, highlights the potential of tigilanol tiglate to deliver meaningful local tumour control in a patient population with limited treatment options.
The study is part of a series of small, rapid Phase II clinical trials to evaluate the drug’s potential across multiple solid tumour indications.
Lead principal investigator for the trial, Professor Kevin Harrington of the Royal Marsden cancer hospital, London, commented: “Our early experience with tigilanol tiglate in diverse head and neck cancers, including a number of difficult-to-treat forms of the disease, has been highly encouraging and suggests promising clinical activity. We look forward to further evaluating its role and determining how it can complement existing treatment options for these patients.”
In the study, 14 of 18 evaluable injected tumours resulted in either complete or partial ablation (reduction in tumour volume), while six tumours achieved complete ablation. The completely ablated tumours remained recurrence free for up to five months.
A total of 64% of response-evaluable patients achieved complete or partial ablation of a treated tumour or tumour segment, meeting the primary efficacy endpoint. Tigilanol tiglate was well tolerated, with most adverse events consistent with its expected local mode of action.
QBiotics Interim CEO and Managing Director, Ebru Davidson, said: “Following on from our highly positive results in Soft Tissue Sarcoma, these results provide further evidence of tigilanol tiglate’s potential to achieve meaningful tumour ablation in solid tumours. An Objective Response Rate of 78% in injected tumours is particularly encouraging in this difficult-to-treat patient population.”
